98%
921
2 minutes
20
Background: It is well known that thrombocytopenia occurs in patients with traumatic brain injury (TBI), and its incidence increases with the severity of injury. We aimed to determine whether postoperative thrombocytopenia in patients with TBI is associated with poor clinical outcomes.
Methods: This was a retrospective cohort study of a large international database called the Medical Information Mart for Intensive Care III (MIMIC-III), which included 1093 patients who underwent TBI surgery. Hospital mortality was the primary endpoint of this study.
Results: Multivariate logistic regression analysis revealed non-thrombocytopenia was significantly associated with a decreased hospital mortality (adjusted odds ratio [OR] 0.49; 95% confidence interval [CI] 0.33-0.75; p = .01). In addition, platelet counts increased over time in both survivors and non-survivors, according to generalized additive mixed model (GAMM). However, the platelet count increased more noticeably in the survivors than in the non-survivors and the difference in platelet count between the two groups showed a trend toward increasing within 7 days after surgery. This difference increased by 7.97 per day on average.
Conclusions: Patients with TBI who experienced postoperative thrombocytopenia were more likely to have a poor short-term prognosis. In addition, we found that the rate of platelet growth over time varied significantly between the survival and non-survival groups. Patients with TBI who experienced a greater early increase in platelet count had a lower mortality rate.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/aas.14244 | DOI Listing |
J Heart Lung Transplant
September 2025
Cardiothoracic intensive care unit; Hôpital Marie Lannelongue, 133 Avenue de la Résistance, 92350 Le Plessis Robinson, France; INSERM U999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, 133 Avenue de la Résistance, 92350 Le Plessis Robinson, France; Pari
Introduction: Antiphospholipid syndrome (APS) is a risk factor for chronic thromboembolic pulmonary hypertension, which is generally treated by pulmonary endarterectomy (PEA). Patients with high antiphospholipid antibody (aPL) titers may be at increased risk for post-operative thrombotic complications. The aim of this study was to investigate potential associations linking APS with high aPL titers to mortality and complications after PEA.
View Article and Find Full Text PDFAnn Med
December 2025
Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Background: Thrombocytopenia (TCP) and coagulation disorders are common complications for patients with liver cirrhosis. The impact of severe TCP [30 × 10/L < platelets (PLT) ≤ 50 × 10/L] and coagulation disorder on bleeding risk after Hassab's operation or partial hepatectomy (PH) for cirrhotic patients is unclear.
Method: Our study retrospectively enrolled 724 cirrhotic patients from July 2019 to August 2024, including 189 patients who underwent Hassab's operation and 535 patients with hepatocellular carcinoma who underwent PH without prophylactic platelet transfusions or thrombopoietin receptor agonists.
Int J Clin Pharm
September 2025
Department of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, 1 Shuanghu Branch Rd, Yubei District, Chongqing, 401120, People's Republic of China.
Introduction: Venous thromboembolism (VTE) is a common and preventable complication in orthopedic surgery, yet adherence to prophylaxis guidelines remains suboptimal. A pharmacist-led anticoagulation care model based on the Pharmacist Early Active Consultation (PEAC) framework may enhance the quality and safety of VTE prevention in surgical patients.
Aim: This study aimed to evaluate the impact of a pharmacist-led Venous Thromboembolism Clinical Pharmaceutical Care (VTE-CPC) model, derived from the PEAC framework, on VTE prevention and anticoagulation quality in orthopedic surgery patients.
Hematol Rep
July 2025
Department of Haematology, Oslo University Hospital, 0372 Oslo, Norway.
Inherited thrombocytopenia (IT) is a heterogeneous group of disorders caused by mutations in over 45 genes. Among these, ANKRD26-related thrombocytopenia (ANKRD26-RT) accounts for a notable subset and is associated with variable bleeding tendencies and an increased risk of myeloid malignancies. However, the extent of this oncogenic risk appears to vary between specific gene variants.
View Article and Find Full Text PDFCureus
July 2025
Anesthesiology and Center for Outcomes Research, University of Texas Health Science Center, Houston, USA.
Heparin-induced thrombocytopenia (HIT) is a rare but serious immune-mediated complication of heparin therapy, often resulting in thrombotic events despite adequate anticoagulation. Rapid-onset HIT is a particularly severe variant that occurs within 24 hours of re-exposure to heparin in sensitized individuals with circulating anti-platelet factor 4 (PF4)/heparin antibodies. Although rare, its potential for rapid progression and fatal outcomes necessitates a high index of clinical suspicion, especially in perioperative settings involving routine heparin use.
View Article and Find Full Text PDF